Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is frequently featured in news coverage as a cloud-native healthcare technology and AI company focused on precision medicine. News about SOPHiA GENETICS often centers on its SOPHiA DDM™ Platform, an AI-powered analytics environment that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
On this news page, readers can follow company announcements related to financial results, platform usage, and strategic direction. Recent press releases have discussed quarterly and preliminary full-year financial performance, including revenue trends, analysis volumes on SOPHiA DDM™, and guidance updates, as well as commentary from management on growth, operating leverage, and non-IFRS metrics.
Another major category of SOPH news involves collaborations and partnerships. SOPHiA GENETICS regularly announces agreements with cancer centers, academic institutions, sequencing technology providers, and biopharma companies. Examples include collaborations to co-develop next-generation sequencing oncology tests, integrate MSK-IMPACT® and MSK-ACCESS® assays powered with SOPHiA DDM™ on external sequencing platforms, and expand access to liquid biopsy and companion diagnostics in specific markets such as Japan.
Product and technology updates also feature prominently. The company has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates virtual representations of patients to simulate potential outcomes in oncology. Additional news highlights include partnerships that integrate SOPHiA DDM™ with sequencing systems to create streamlined, end-to-end workflows for next-generation sequencing and precision oncology research.
Investors, clinicians, and researchers who follow SOPH news can use this page to track developments in AI-driven precision medicine, including new applications on the SOPHiA DDM™ Platform, expansions of its global customer network, and collaborations aimed at advancing cancer and rare disease research.
SOPHiA GENETICS (Nasdaq: SOPH) has achieved a significant milestone by analyzing over two million patient genomic profiles through its AI-powered SOPHiA DDM™ Platform. This achievement, announced at NVIDIA GTC, represents a doubling of analyzed profiles since 2022.
The platform currently serves 800 healthcare institutions across 72 countries, processing thousands of oncology and rare disease cases daily. SOPHiA DDM™'s AI capabilities are uniquely shaped by real-world data, enabling faster and more accurate treatment decisions.
Healthcare professionals worldwide have reported significant benefits from the platform:
- CHU Lyon, France reports faster and more efficient analysis of hereditary cardiac pathologies
- Karkinos Healthcare in India has expanded advanced cancer diagnostics to underserved communities
- Fondazione Policlinico Universitario Gemelli in Italy utilizes the platform for various genetic analyses
- UCSF Clinical Cancer Genomics Lab successfully identifies complex genetic rearrangements in cancer cases
SOPHiA GENETICS (SOPH) reported Q4 2024 revenue of $17.7M, up 4% YoY, and full-year 2024 revenue of $65.2M, also up 4% YoY. The company achieved record analysis volumes with 352,000 analyses in FY2024, representing 11% YoY growth.
Key operational metrics include:
- Q4 gross margin of 68.2% (reported) and 74.2% (adjusted)
- Operating loss improved by 8% to $17.4M (reported) and 23% to $10.2M (adjusted)
- Reached 472 core genomics customers, up from 450 in Q4 2023
- Signed 92 new customers in FY2024
For 2025, SOPHiA GENETICS projects revenue between $72M-$76M (10-17% growth) and adjusted EBITDA loss between $35M-$39M. The company expects to approach adjusted EBITDA breakeven by end of 2026 and achieve positive adjusted EBITDA in H2 2027.
SOPHiA GENETICS (Nasdaq: SOPH) has announced significant adoption of its MSK-ACCESS® and MSK-IMPACT® cancer testing applications powered by SOPHiA DDM™. Thirty-seven prominent institutions globally have adopted these recently launched Liquid Biopsy and Solid Tumor applications, with thirty-four specifically choosing MSK-ACCESS® within ten months of its launch.
Notable adopters include Heidelberg University Hospital, Hospital del Mar, Jewish General Hospital, and the Jiménez Díaz Foundation. The decentralized deployment enables institutions to conduct world-renowned testing in-house, offering less-invasive options for patients with potentially lower costs and faster turnaround times.
This milestone follows SOPHiA GENETICS' 2023 partnership with Memorial Sloan Kettering Cancer Center and their October 2024 agreement with AstraZeneca to accelerate MSK-ACCESS® deployment globally. The company launched MSK-IMPACT® for Solid Tumor testing in November 2024.
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, before U.S. markets open. The company will host a conference call at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the financial results and business outlook. The call will be available via webcast on the SOPHiA GENETICS Investor Relations Website, with a replay option provided after the event.
SOPHiA GENETICS (SOPH) has launched the OncoPortal™ Mutation Tracker, a new longitudinal MRD tracking tool for oncology disease monitoring. This add-on module for the SOPHiA DDM™ Platform enables tracking of genomic variants across multiple time points in cancer patients.
The tool combines longitudinal tracking capabilities with next-generation sequencing (NGS) to detect cancer-specific genetic mutations at very low frequencies. Key features include flexible low frequency variant selection, customizable threshold settings, and reporting features that generate longitudinal graphical representations.
According to Dr. Philippe Menu, Chief Medical Officer, the ability to track low frequency variants longitudinally is revolutionary as it enables detection of minimal cancer traces that might escape traditional testing methods. Dr. Christophe Marzac from Gustave Roussy Institute praised the interface as a important solution for broader NGS adoption among oncologists.
SOPHiA GENETICS (SOPH) has globally launched MSK-IMPACT® powered with SOPHiA DDM™, a comprehensive genomic profiling application developed in collaboration with Memorial Sloan Kettering Cancer Center. The solution enables organizations worldwide to access advanced tumor profiling technologies with high accuracy and efficiency. The platform demonstrates exceptional performance with 99.3% positive agreement for SNV/Indel detection and 94.6% for CNV detection. SOFIVA GENOMICS in Taiwan is among the first adopters, expanding their tumor profiling capabilities. The workflow takes approximately five days from DNA extraction to final report, integrating OncoKB™ for enhanced analytical insights.
SOPHiA GENETICS (Nasdaq: SOPH) has announced key leadership changes effective November 5, 2024. Ross Muken, previously CFO and COO, has been promoted to company President, where he will oversee global business operations and strategic planning alongside CEO Jurgi Camblong. George Cardoza joins as the new CFO, bringing over 30 years of experience in precision medicine and clinical diagnostics. Cardoza, who previously served as CFO at Biocartis and held executive roles at NeoGenomics Laboratories and Quest Diagnostics, will oversee all corporate finance functions including accounting, FP&A, investor relations, internal audit, tax, and treasury.
SOPHiA GENETICS (SOPH) reported Q3 2024 financial results with revenue of $15.9 million, down 2.8% year-over-year. The company achieved gross margins of 67.2% (reported) and 73.1% (adjusted). Operating loss improved to $15.4 million (reported) and $10.6 million (adjusted), showing improvements of 7.1% and 10.4% respectively. Cash burn decreased significantly by 39.1% to $9.6 million. Clinical analysis volume grew 16% year-over-year, despite BioPharma softness. The company maintains its full-year guidance of $65-67 million in revenue, 72.0-72.5% adjusted gross margin, and adjusted operating loss between $45-50 million.
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has announced the release date for its third quarter 2024 financial results. The company will disclose its financial performance before U.S. markets open on Tuesday, November 5, 2024. Following the release, SOPHiA GENETICS will host a conference call at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the financial results and provide a business outlook. Investors and interested parties can access the webcast live on the SOPHiA GENETICS Investor Relations Website. For those unable to attend the live call, a replay will be made available on the company's website after the event's conclusion.
SOPHiA GENETICS (Nasdaq: SOPH) will present groundbreaking research at ESMO 2024, showcasing AI-driven patient stratification for non-small cell lung cancer (NSCLC) treatment. The study, conducted with AstraZeneca, analyzed the POSEIDON Phase 3 clinical trial using multimodal machine learning to identify NSCLC patient subgroups most likely to benefit from combination immunotherapy.
The research revealed signatures associated with higher overall survival benefit from adding tremelimumab to durvalumab and chemotherapy in first-line treatment of metastatic NSCLC. Key genetic factors included EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation. This approach could significantly impact NSCLC treatment by enabling more personalized care strategies.
FAQ
What is the current stock price of Sophia Genetics Sa (SOPH)?
What is the market cap of Sophia Genetics Sa (SOPH)?
